TOXIC OLIGOMERS / JUNE DATAThe incidence of Alzheimer's disease (AD) is growing every day and finding an effective treatment is becoming more vital. Amyloid-β (Aβ) has been the focus of research for several decades. The recent shift in the Aβ cascade hypothesis from all Aβ to small soluble oligomeric intermediates is directing the search for therapeutics towards the toxic mediators of the disease. Targeting the most toxic oligomers may prove to be an effective treatment by preventing their spread. Specific targeting of oligomers has been shown to protect cognition in rodent models. Additionally, the heterogeneity of research on Aβ oligomers may seem contradictory until size and conformation are taken into account.
Now with 1A about to be released in June and further dosing capabilities and blood brain barrier data, then we can assume that we can slow or stop the propagation of toxic oligomers and be the only antibody that has no brain edema (Aria E) and ultimately will be given fast track designation by the FDA. Now if that doses not get the markets excited, nothing will.